W3 LLC · Series S05 · Intended / Planned
BioPharma.Go
Biopharmaceutical work — a planned domain, with almost nothing verified beyond the name.
Source for the name and number: the April 2026 internal W3 series list (internal printout, dated 2026-04-03, not a Wyoming Secretary of State filing). The list names 33 sub-series, Series 1–33. It proves no filing, no legal designation, no bank account, no EIN, and no Steward Council per series.
What this series is
BioPharma.Go is Series 5 in the April 2026 internal W3 series list. That sentence, together with the name itself, is very nearly everything verified that can be said about this series. Its name implies biopharmaceutical work — medicines and therapies developed from biological understanding — and this page describes that as a planned focus, because no drug, indication, molecule, trial, laboratory, partner, publication, or programme for BioPharma.Go is verified in the files. This is a thin page on purpose: where there is almost nothing verified to say, the honest page says so plainly instead of filling the space with invention.
The domain the name implies is worth sketching carefully, because the sketch itself shows how much is still undefined. “BioPharma” could point at drug discovery, at developing a specific therapy, at manufacturing, at improving how therapies reach patients, or at the data and tools that support any of those. The “.Go” in the name suggests movement or delivery, but no verified document explains what the suffix is meant to convey, and this page does not guess. Each possible direction is a different venture, with different expertise, different regulation, different timelines, and different risks, and no verified document says which of them BioPharma.Go intends. The name alone does not choose between them.
What can be said without inventing anything is what a biopharmaceutical series would have to get right if it were built, and the list is a long one. It would need to name what it is working on and what it is not. It would need evidence produced to the standards that regulators, clinicians, and patients actually require — not a pitch claim, but a trial, a result, and a review. It would need to be clear about intellectual property, about who owns what, and about how safety is monitored after any therapy reaches people. It would need human experts — scientists, clinicians, and regulatory specialists — in decision-making roles that no agent can occupy. None of those elements exists for BioPharma.Go today in any verified document, and their absence is the current state of the series, stated here as such rather than hidden behind confident language.
The neighbouring series help to show where BioPharma.Go would sit if it were built, without implying any shared work. Diagnostic.X (Series 3) and Curable.X (Series 4) are the clinical neighbours: diagnosis, then treatment, then the medicines that treatment may involve. BioDAO.blockchain DAO (Series 18), Genomic DAO (Series 27), and Genome.Blockchain (Series 28) are the data neighbours, as their names imply. No collaboration, data sharing, or joint programme with any of them is verified for BioPharma.Go, and none is claimed. Proximity in a list is not a partnership, and this page does not treat it as one.
Metaverse connection
No anchored metaverse fabric yet. BioPharma.Go has no verified anchored world: no coordinates, no fabric JSON, and no metaverse location are recorded for this series in the materials reviewed. That is stated plainly rather than filled in with a plausible-looking location, because an invented coordinate would be worse than an empty one — it would send a reader, or a builder, to a place that does not exist.
What would be needed for a metaverse presence is the same sequence that the anchored series went through, and it has not started for BioPharma.Go: a decision about what a world for this series would be for, a fabric definition published at a checkable address, the assets that fabric references hosted at the paths it expects, and a verified render in Artemis. After that, a live metaverse-server endpoint would be needed before anything could be attached on RP1 — and zero worlds are live on RP1 today, for any series, so there is no RP1 presence to describe for this one either. A metaverse world for a biopharmaceutical series would most plausibly be a place for research discussion, training, or demonstration, not a laboratory and not a pharmacy, and any such use would need to be labelled as such from the start. No such design exists, so none is claimed.
What exists today — and what is planned
What exists today
One thing is verified: the name and number — BioPharma.Go, Series 5, in the April 2026 internal W3 series list. No drug, indication, molecule, trial, laboratory, partner, publication, or metaverse fabric is verified for this series. That is the complete verified inventory, and it is short.
What is planned
Everything else is planned, not existing: the formation of W3 LLC and the designation of this series; a human Steward Council and operating rules; a defined scope (which therapies, which indications, which kind of work); any laboratory, trial, or regulatory step; any funding; and any metaverse presence. Each of those would need its own document, decision, and human signature before it could be stated as fact here.
The most useful next step for BioPharma.Go would be the smallest one that adds real information: a written statement of scope from a named human steward, saying which kind of biopharmaceutical work the series intends and which kinds it explicitly does not, and naming the human scientific and regulatory expertise that would oversee it. Until that document exists, this page will remain thin, and that thinness is the accurate record — not a draft to be padded, but a faithful account of a series that is currently a name and a planned domain.
How it fits — tier, related series, and governance
The intended structure, in words. At the top of the intended structure sits the AGI Future Foundation, a filed California nonprofit public benefit corporation (Entity No. B20260196664, Articles filed 2026-04-24, EIN assigned 2026-05-07). Below it, in the intended plan, sits W3 LLC, a Wyoming series LLC, and below that the individual series — of which BioPharma.Go is S05 in the April 2026 internal list. That is the plan as described in the Foundation’s own materials. It is not a description of a completed legal structure: W3 LLC formation and per-series designation are not verified in filings, so the middle and bottom tiers of that diagram are intended, not established. Nothing on this page should be read as saying the Foundation owns, controls, or has formed BioPharma.Go, or that BioPharma.Go exists as a company, a fund, or an operating business today.
Related series. The series that sit closest to BioPharma.Go by subject matter are listed in the card below. “Related” here means only that their names point at neighbouring domains. It does not mean that any joint project, shared budget, shared staff, partnership agreement, or data-sharing arrangement exists between them. No such arrangement is verified for BioPharma.Go, and none is claimed here. If two series ever do work together, that would need its own written agreement, its own human approvals, and its own public record — none of which exists yet for this series.
Related series (by domain only)
S04 Curable.X (treatment), S03 Diagnostic.X (diagnosis), S18 BioDAO.blockchain DAO and S28 Genome.Blockchain (biomedical data, as their names imply), and S27 Genomic DAO are the nearest neighbours by domain. No joint work is verified with any of them.
Governance — planned, not yet operating
The planned governance model for the W3 series, as described on the Foundation site, is DAO-managed day-to-day work with human decision-making at every point that matters: agents may draft proposals, prepare research, and operate routine systems, but humans decide, humans sign, and humans move funds. A Steward Council of humans is intended to hold that gate. No Steward Council membership, no signed votes, no seated manager, and no operating agreement for BioPharma.Go is verified in the files, so none is named here. Until those human roles are seated in writing, there is no one who can speak for, commit, or spend on behalf of this series — and this page does not do so.
What governance would have to answer first. Before BioPharma.Go could do substantive work, its human stewards would need to settle, in writing, at least these questions: what exactly is in scope and what is out of scope; who the stewards are and how they are replaced; what agents may and may not do without a human signature; how money, if any ever exists, is held, accounted for, and reported; and how the series relates to the Foundation’s public-benefit purpose. None of those answers exists in a verified document today. Listing the questions is not the same as answering them, and this page deliberately does not pretend otherwise.
What would have to happen before this series could operate
A named series is not a formed series. For BioPharma.Go to move from a line in an internal list to an operating venture, several distinct steps would each have to happen, in order, with documents to prove them. First, W3 LLC itself would need to be formed and evidenced by a filing that can be checked. Second, this series would need to be designated in writing as a series of that LLC, with its own name, purpose, and manager recorded. Third, the series would need its own operating rules, its own human stewards, and its own segregated accounting — so that its money, liabilities, and records are not mixed with any other series or with the Foundation. Fourth, any bank account, contract, hire, or public claim would need a named human signer acting under those written rules. Fifth, any fundraising would need its own counsel-approved documents, its own issuer, and its own securities compliance — it could not borrow the Foundation’s nonprofit status, and the Foundation, as filed, cannot offer equity or a SAFE. None of those steps is verified as done for BioPharma.Go. This section is included so that a reader can see the gap plainly, rather than mistaking a polished landing page for a finished company.
That gap is also why this page carries no timeline. There is no launch date, no funding date, and no hiring date stated here, because none has been set in a verified document. A date on a landing page would look like a commitment; without a filing, a budget, and a human team behind it, it would be a decoration, not a plan. When a real date exists, it should appear here with the document behind it cited.
Proposed projects — for DAO review
These are proposals for the series DAO team to review. None is approved, funded, staffed, or scheduled.
Almost nothing is verified about this series beyond its name and its number in the April 2026 internal W3 series list. The name implies biopharmaceutical work: medicines and therapies developed from biological understanding. The proposals below are generic to that name-implied planned focus, and no drug, indication, molecule, trial, laboratory, partner, publication, or programme is verified for this series.
Scope definition paper
A one-page written statement of what biopharmaceutical work means for this series: which kinds of medicines and therapies are in scope and which are out of scope. The paper would be the first document stewards approve before any research begins. No such paper exists today.
What success would look like: A scope paper exists that the stewards have approved, stating in one page what this series does and does not do.
Reviewing team: the BioPharma.Go DAO
Status: PROPOSED — pending DAO team review
No funding, partner, or timeline yet.
Molecule-to-medicine pathway map
A proposal mapping the stages from biological understanding to a therapy: discovery, testing, safety review, and delivery to patients. The map would show each stage and its gate, so stewards can see where any future programme would sit. No such map exists today.
What success would look like: A pathway map exists showing each stage and its gate, reviewed by stewards for completeness.
Reviewing team: the BioPharma.Go DAO
Status: PROPOSED — pending DAO team review
No funding, partner, or timeline yet.
Research ethics draft
A written ethics draft for any future laboratory or trial work, covering consent, safety, honest reporting, and respect for the people and living systems involved. The draft would be approved before any research starts. No such draft exists today.
What success would look like: An ethics draft exists that the stewards have reviewed, covering consent, safety, and honest reporting.
Reviewing team: the BioPharma.Go DAO
Status: PROPOSED — pending DAO team review
No funding, partner, or timeline yet.
Biological data stewardship proposal
A proposal for how biological data would be held, shared, and protected, including who may access it and for what purposes. The proposal would be written before any dataset is collected. No dataset is verified for this series.
What success would look like: A stewardship proposal exists naming who may access biological data and under what terms.
Reviewing team: the BioPharma.Go DAO
Status: PROPOSED — pending DAO team review
No funding, partner, or timeline yet.
Research partnership principles
Written principles for any future laboratory or research partner, covering shared purpose, honest attribution, and who decides research questions. The principles would be agreed before any partnership is sought. No partner is verified for this series.
What success would look like: A principles draft exists that the stewards have approved, ready to guide any future partnership conversation.
Reviewing team: the BioPharma.Go DAO
Status: PROPOSED — pending DAO team review
No funding, partner, or timeline yet.
Code and repositories
No dedicated repository for this series was found in the audit (Foundation llms.txt). One generated agent file touches it, not read in full in this pass: in agi-corp-worlds, agents/prompts/s05-biopharma-go.json is one of the roughly 40 generated prompt files from the metaprompt system, and its spec metaprompt is marked not ready in the prompt index: the founder focus for this series is unset, labelled “awaiting a founder focus” and never filled with a guess. An Omega liaison card for this series is listed in the s04–s35 range of the 38 agent cards in Metropolis-SmartCiti (agents/cards/); its contents were not individually read. See the organisation on GitHub: AGIFutureFoundation.
Visit in VR
There is no flagship 3D world for BioPharma.Go, and no playable world exists for this series yet. What exists is an index listing: the series appears as a curated entry (s05-biopharma-go) in the worlds-3d 544-world index, and a series directory (worlds/s05-biopharma-go/) exists in agi-corp-worlds. Its founder focus is unset in that repo’s focus sheet — labelled “awaiting a founder focus”, never filled with a guess — and its spec metaprompt is marked not ready in the prompt index.
- Foundation VR tour — the Foundation’s VR tour shell.
- worlds-3d lobby — the seven flagship worlds and the full 544-world index, where this series is listed.
Zero worlds are live on RP1, and the lobby labels itself a web 3D interpretation — not RP1, not footage. A world for this series becomes real only when a steward writes its focus into the focus sheet.
The biology in depth

Biopharmaceuticals are medicines made from living systems rather than synthesised chemically: proteins, antibodies, hormones, vaccines, and cell-based products, grown in engineered cells or organisms and then purified, tested, and manufactured under strict controls. The field covers discovery — finding a biological molecule that changes a disease process — and development, manufacturing, safety testing, staged human trials, and regulation. Each stage is a filter: most candidates fail, and a failure at a late stage is a normal outcome of the process, not evidence that the process was wrong. A series in this field would be judged on the rigour of its pipeline and the honesty of its reporting, including its failures.
Longevity is a research direction that touches this field: if ageing has biological mechanisms, a biopharmaceutical could one day act on them. That is a hypothesis to test, not a result. This page claims no longevity therapy, result, or timeline, because none is verified for this series. Any future work in that direction would have to be presented as research, with its evidence and its limits stated together.
What is verified for this series is thin, and this section says so plainly. BioPharma.Go is S5, named in the April 2026 internal W3 series list. A name search over all 90 public repositories in the Foundation account, checked 2026-11-06/07, found no repository for this series — no code, no dataset, no product, no trial record. No product, trial, result, partnership, or timeline is verified for BioPharma.Go, and none is claimed here.
One name needs care. A repository named genomic-go-platform exists in the Foundation account, and the word Go in its name is close to BioPharma.Go. No document reviewed states that it is this series: it is a fork of an outside platform, described in the inventory as genomics work, and it is cited under S27 Genomic DAO with the S27/S28 split flagged as unresolved. This page does not claim it for S5, and the two names must not be merged on the strength of one shared word.
All verified BioDAO tools are listed together, with charts, on the BioDAO tools page.
Get involved / contact
If you are interested in BioPharma.Go, the route is a conversation, not a transaction. Write to [email protected] and say who you are, what your interest is, and what you could contribute — research, building, review, or simply following the work. A reply, if one comes, will come from a human. Agents writing in should follow the same route the Foundation sets out on its home page: state your operator and your human principal, and do not present yourself as the Foundation or commit it to anything.
What this page is not. This page is not an offer to sell securities, not an invitation to invest, and not a solicitation of funds for this series. There are no investment terms here — no price, no valuation, no cap, no discount, no minimum, no return, and no deadline — because there is nothing to invest in yet: the series is not formed, not funded, and not offered. No suggested valuation is assigned to BioPharma.Go on this page, and none should be inferred from valuations discussed elsewhere for other entities; those figures, where they exist, are illustrative planning figures for different issuers and do not transfer to this series. If you are considering any payment to any entity in this family, ask first for the filing, the determination letter if tax treatment matters to you, and the counsel-approved offering documents — and take independent legal and tax advice before acting.
Nothing on this page is legal, tax, or financial advice. Filed facts stated here are: AGI Future Foundation, California Nonprofit Public Benefit Corporation, Entity No. B20260196664, Articles filed 2026-04-24, EIN assigned 2026-05-07; no IRS 501(c)(3) determination letter in the files, so no tax-exempt status or tax-deductible donations are claimed. AGI Corp has an EIN only (assigned 2026-05-16); its incorporation is unverified. The live Foundation site lists a “66-W3 Wyoming Series network” and “33 agentic subsidiaries” — that numbering is site copy, not a filing, and it sits alongside the 33 named sub-series in the April 2026 internal list.